June 11, 2020 -- Oblique Therapeutics has used its Abiprot antibody discovery platform to identify an epitope in SARS-CoV-2 that may facilitate the generation of new neutralizing antibodies to treat COVID-19.
Abiprot is based on a tailored molecular reporter system and proteomics. The system can identify high-affinity antibody binding sites in any given protein with single-amino acid resolution.
By working to map additional epitopes on the SARS-CoV-2 surface isolated from the nasal swab of a COVID-19 patient, the company identified the new epitope in a pilot study. The company will make all of the results freely available for vaccine and antibody-developing pharmaceutical and biotechnology companies.
The research to discover the epitope was conducted in collaboration with scientists from institutions in Sweden including Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, and Karolinska Institute with support from Nanoxis Consulting.